Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phago-Intesti
- Development stage
- Unknown
- Lead developer
- Eliava Biopreparations
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
Phago-Intesti is a therapeutic bacteriophage cocktail developed by Eliava Biopreparations for the treatment and prevention of acute and chronic intestinal infections. The preparation consists of a sterile filtrate of phage lysates that specifically target and lyse a broad spectrum of enteric pathogens, including *Shigella*, *Salmonella*, *Escherichia coli*, *Proteus*, *Staphylococcus*, *Pseudomonas aeruginosa*, and *Enterococcus*. The mechanism of action involves the specific attachment of bacteriophages to receptors on the surface of target bacterial cells, followed by the injection of viral genetic material, replication within the host, and subsequent lysis (destruction) of the bacteria. This biological process effectively reduces the pathogen load without disrupting the commensal intestinal microflora. Phago-Intesti is classified as a paratherapeutic product and is typically administered as an oral or rectal solution.
- Brand names
- Phago-IntestiIntesti-phageIntesti Bacteriophage
- Other names
- Intesti-phageIntesti Bacteriophage
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on Phago-Intesti.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phago-Intesti.